Objective: To evaluate outcomes of fluorinated corticosteroids, with or without other medications, for treatment of congenital heart block in-utero. Study design: A search was conducted through MEDLINE, EMBASE, WEB OF SCIENCE and SCOPUS from inception to October 2017. Only comparative studies are considered eligible. Outcomes include fetal death, downgrade of heart block, neonatal death, need for neonatal pacing, fetal and maternal complications. Random effects model was used.
Introduction
Congenital heart block (CHB) is a rare fatal condition that may eventually lead to fetal demise, neonatal death, or permanent pacemaker implantation [1] . Incidence of CHB is approximately 1 in 20,000-30,000 live births [2] . CHB may occur in a structurally normal heart (isolated CHB) as a complication of maternal autoimmune disease or in fetuses with congenital heart defects (complex CHB) [3] .
The incidence of CHB is 2% among women with Ro-positive antibodies without previously affected offspring, 15-20% among women with Ro-positive antibodies and with previously affected offspring, and 5% among women with mixed connective tissue and/or Sjögren Syndrome [4] [5] [6] . Among fetuses exposed to anti-Ro antibodies, 17.5% may be complicated by fetal demise, and 70% would eventually need permanent pacemaker implantation in the 10 years of life [7] . Permanent pacemaker implantation has been considered the only intervention that improves survival rate among neonates with CHB [8, 9] .
Prenatal diagnosis of CHB can be achieved early in the second trimester, either incidentally during intermittent auscultation or during anatomical survey ultrasound, and can be confirmed by fetal echocardiogram with Doppler techniques to determine level of heart block and verify any underlying major structural heart lesions. Therefore, several studies investigated a possible role of immediate post-diagnosis fetal therapy to improve fetal and neonatal outcomes of CHB. Treatment options include fluorinated and non-fluorinated corticosteroids, immunoglobulins or combined treatment. The aim of treatment is to reverse or downgrade CHB and to prevent intrauterine progression of the disease which can be manifested as hydrops fetalis, pericardial effusion, cardiomegaly, which impacts overall survival rate and lines of treatment [10] .
In this study, the aim is to summarize the effect of fetal treatment of CHB with fluorinated corticosteroids, with or without other medications, on fetal and neonatal survival rates and the need for permanent pacemaker implantation. We also aimed to evaluate potential maternal and fetal complications associated with prenatal treatment.
Materials and methods

Literature search
The authors conducted a literature search for studies that assessed maternal, fetal and neonatal outcomes among pregnant women whose fetuses were diagnosed with congenital heart block during pregnancy. Studies that compared the use of fluorinated corticosteroids with or without other medications in comparison to no treatment during pregnancy. The search covered MEDLINE, EMBASE (with online Ovid interface), WEB OF SCIENCE and SCOPUS and was done in collaboration with an expert librarian. Studies conducted from the date of database inception to October 2017 were included. We used the following search terms: "Treatment" OR "management" AND "fetal" OR "congenital" OR "in utero" AND "heart block" OR "aterioventricular block". Search was set to filter out conference papers and review articles. In addition, manual search on additional references was achieved by reviewing references of articles retrieved by initial search. The detailed search strategy is appended (Appendix I). The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS) [11] Eligibility criteria and study selection After conduction of literature search, 2 reviewers performed independent screening of titles and abstracts to exclude irrelevant studies. After exclusion of irrelevant studies, we reviewed the full text of the remaining studies for final selection of eligible articles. Minor discrepancies in data were adjudicated by consensus among reviewers. Comparative studies that address obstetric and neonatal outcomes among pregnant women who and who did not receive fluorinated corticosteroids (with or without other medications) to manage congenital heart block. Case reports, case series, and single arm studies were not included. However, neither language nor sample size was considered for exclusion.
Fetal death, downgrade of heart block, development of hydrops, average intrauterine fetal heart rate, neonatal death, and the need for neonatal pacing present our primary outcomes. Secondary outcomes were fetal and maternal complications that could be potentially related to treatment e.g. oligohydramnios, intrauterine growth restriction (IUGR). These outcomes were analyzed separately. However, average intrauterine fetal heart was not included in final analysis because documentation was missing in the majority of selected studies.
Data abstraction
A standardized form was designed for abstraction of data from selected studies. The form consists of study authors, study origin, type of study, time frame during which the study was conducted, sample size, gestational age at diagnosis, maternal and fetal risk factors, selection criteria of study population, study arms, type of medications used,duration of intervention and studied outcomes. The form also included primary and secondary outcomes as listed above.
Data analysis
Binary outcomes were expressed as odds ratios (OR) and 95% confidence interval (CI). Due to anticipated heterogeneity, pooling of results was performed using random-effect model [12] .
Heterogeneity was evaluated using I squared statistic. I squared value over 50% is consistent with substantial heterogeneity [13] . Review Manager (RevMan) Version 5.3 was used to conduct statistical analysis for this review (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) [14] . 
Results
Database search yielded 923 articles. Preliminary screening of titles allowed exclusion of 706 articles for irrelevance. Reviewing abstracts of the remaining 217 articles, 87 were excluded for irrelevance, 26 were case reports, 23 were review articles. Full texts of the remaining 38 articles were retrieved. Of those 38 articles, 16 articles meet our inclusion criteria ( Fig. 1 ). Summary of study demographics and study design is illustrated in Tables 1 and 2 [7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Appendix II summarized risk of bias of included studies.
Comparing fetuses diagnosed with CHB who were treated with fluorinated steroids with or without other treatment options to fetuses who were not exposed to any treatment, 12 studies reported the rate of fetal death. The rate of fetal death among exposed group was 9.5% (33/347) compared to 9.16% (36/393) in the non-exposed group, the difference was not statistically significant (OR 1.10, 95% CI 0.65-1.84), I square value is 0%. Downgrading of CHB was reported in 8 studies. The incidence of downgrading was reported in 9.5% (22/ 232) versus 1.8% (5/283) in treated and non-treated groups, respectively. The difference was statistically significant (OR 3.27, 95% CI 1.23-8.71) with I square value of 0%. There was no significant difference in the incidence of neonatal death between both group as reported in 11 studies (9.1% [25/276] in the treated group versus 11.3% [34 / 300] in the untreated group, OR 0.98, 95% CI 0.41-2.33). I square value is 38%. Also, twelve studies assessed the need for pacing among treated and untreated fetuses, which was reported in 54.35% of the treated group (181/333) versus 46.56% (183/393) of the untreated group (OR 1.46, 95% CI 0.78-2.74). Data on this outcome yielded substantial heterogeneity (I square value is 62%) (Fig. 2) .
Subgroup analysis of studies was conducted for studies that compared steroids only to no treatment. In 4 studies, fetal death was 9.2% (12/130) in the treated group and 8.8% (15/171) in the untreated group (OR 1.18, 95% CI 0.51 -2.73, I square value is 0%). CHB downgrading was documented in 4 studies. The incidence was 9.7% (13/134) and 2.6% (5/195) (Fig. 3) .
The incidence of oligohydramnios was documented in 7 studies. Among all treated fetuses, the incidence of oligohydramnios was significantly higher in the treated group ( Similarly, 4 studies showed that the incidence of IUGR is 19% (20/ 105) in the treated group compared to 6.8% (8/117) in the untreated group, which is statistically significance (OR 3.61, 95% CI 1.43-9.13), 
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I square value is 0%. Similarly, the incidence of maternal complications was higher among the treated than untreated group as reported in 6 studies (4.4% [8/183], 0% [0/229], OR 4.28, 95% CI 1. 16-15.86 ). I square value is 0% (Fig. 4 ).
Discussion
Several therapeutic options have been investigated to achieve early prenatal management of congenital heart diseases including CHB with the aim of reducing significant morbidity and mortality in utero [30] . In this systemic meta-analysis, we investigated the potential role of fluorinated steroids, alone or in combination with other medical options, to improve intrauterine or postnatal outcomes of CHB. According to our results, the use of fluorinated steroids, either alone or in combination with sympathomimetic drugs, did not reduce the rate of fetal death, neonatal death, or the rate of neonatal pacing compared to no intervention. Medical treatment showed superiority to no intervention in the incidence of CHB downgrading. This advantage is not evident with the use of fluorinated steroids alone. However, this effect does not seem to be clinically significant. On the other sides, as medical intervention was administered from the time of diagnosis to the time of delivery in most studies, our results also showed increased risk of oligohydramnios, IUGR and maternal complications among women receiving medical treatment for CHB compared to no intervention.
Understanding the etiology and mechanism of CHB may clarify the theoretical basis of prenatal medical treatment. CHB secondary to fetal cardiac structural anomalies typically yields poor prognosis known for a congenital heart disease [31] . Poor prognosis is not fully understood. However, it is likely related to the underlying disease which contributes to complexity of care [31] . In these cases, in-utero administration of beta-receptor agonists may increase fetal heart rate to above 55 beats / minute. Beta-adrenergic agonists act on both atrial and ventricular rates with varying response due to defect in the A-V node or other anomalies of the conduction system of the heart [32] . They seem to act locally with no neural affection during the stimulation process of primary (i.e., atrial) and secondary (i.e., ventricular) pacemakers or even theoretical suggestion that there is a nodal pacemaker responsible for heart rate acceleration under effect of beta receptor agonists [32] . However, long-term outcomes including survival did not improve. Moreover, fetal Tachycardia with arrhythmia and maternal tachycardia were reported as complications [30] [31] [32] . On the other side, CHB secondary to maternal immunological disorders is likely related to immune response in form of inflammation and fibrosis, which subsequently damages conduction fibers and myocardium. Therefore, a proposed treatment approach would be to control immune response before permanent tissue damage occurs [33] . Nevertheless, plasmapheresis as well as intravenous injection of immunoglobulin (to decrease serum levels of anti-Ro and La antibodies) did not produce long term satisfactory results [34] [35] [36] . The familiar antimalarial agent Hydroxychloroquine (HCQ) plays a big modulating role in the action of toll-like receptor ligation and signaling which in turn affects the inflammatory process and fibrosis in cardiac tissue [37, 38] . The effect of HCQ in decreasing the incidence of fetal heart block makes it a good alternative for traditional lines of treatment. However, HCQ use is still limited. This is mostly attributed to the lack of confirming prospective studies and its probable hearing and visual adverse effects [39] . Combination of plasmapheresis and immunosuppressive medications, including cyclophosphamide and azathioprine, was also investigated in pregnant women with Sjögren's syndrome with good results. However, evidence was limited to case reports [40] [41] . An alternative option is fluorinated steroid preparations, which have been investigated because of their anti-inflammatory proprieties, availability, easy administration and low cost [30, 34, 42] . It has been known that auto-antibodies have role in pathogenesis of congenital atrioventricular block through mediating several inflammatory processes of conductive system of fetal heart and reduction of L-type calcium channels [43] [44] [45] [46] . Pharmacologically placental 11ß-hydroxysteroid dehydrogenase complex inactivates maternal active prednisolone but minimally affects fluorinated steroids so dexamethasone and betamethasone are available to fetus in active form. [47] . On the other hand, nonfluorinated steroids are present in fetal circulation in inactive form because of immaturity of fetal hepatic function. [34] . Maternal administration of dexamethasone is effective in modulating immunological reactions and subsequent inflammation and fibrosis [27, 48, 49] . Initial studies have shown potential benefits when used alone or in combination with other medications [17, [50] [51] [52] , which ranges from regression of the disease to first degree or sinus rhythm [15, 53, 54] to resolution of pleural and/ or pericardial effusion complicating CHB [15] . Steroid treatment was initiated around the twentieth week of gestation when universal sonographic examination is usually performed as the onset of disease process is thought to start as early as the sixteenth week of gestation [55, 56] . Data on the role of fluorinated steroids to prevent the development of CHB among high risk population is still limited [34] .
In this meta-analysis, fluorinated steroids were not superior to no-treatment except in the incidence of downgrading of CHB after initiation of treatment. However, some reviews have reported that transplacental steroid rarely reverse complete CHB, the fact that may explain the lack of improvement of outcomes despite steroid downgrading effect [57, 58] . In addition, our results raise serious concern on the risk of oligohydramnios and IUGR, particularly as regimens described in these studies include high dose and/or prolonged use of corticosteroid. Brucato et al. [59] reported neurodevelopmental adverse effect of fluorinated steroids, which may be less prominent with betamethasone than dexamethasone. Several studies also reported the association between prenatal steroid administration and maternal adverse effects as gestational diabetes and hypertension, which is also consistent with our findings [16, [22] [23] [24] 49, 50, 54, 60] The results of this review emerge from a total of more than 1000 cases, which presents an advantage of this study. The review investigated possible direct and indirect benefits of fluorinated steroids as well as their potential disadvantages. However, limitations include inconsistency in treatment regimens, retrospective nature of many studies and deficiency of some critical data including development of plural effusion and ascites with and without treatment.
In conclusion, fluorinated steroids do not provide significant benefit in fetuses with CHB. With the exception of CHB downgrading, it does not improve fetal or neonatal survival. On the other hand, prolonged regimens are associated with increased risk of fetal and maternal complications. Therefore, their use for this indication is not recommended.
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